Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells $754,600.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Randal Scott sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the transaction, the director directly owned 11,589 shares of the company’s stock, valued at $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

BridgeBio Pharma Stock Down 3.6%

NASDAQ:BBIO opened at $68.14 on Friday. The firm has a market capitalization of $13.13 billion, a PE ratio of -16.30 and a beta of 1.13. BridgeBio Pharma, Inc. has a 12-month low of $28.33 and a 12-month high of $84.94. The firm has a 50-day moving average price of $75.52 and a 200 day moving average price of $63.98.

Analyst Ratings Changes

BBIO has been the subject of several recent analyst reports. Truist Financial increased their price objective on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Leerink Partners lifted their price target on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Oppenheimer boosted their price target on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Finally, Evercore reaffirmed an “outperform” rating on shares of BridgeBio Pharma in a report on Monday, October 27th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $82.05.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of BridgeBio Pharma in the second quarter worth about $25,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd bought a new position in BridgeBio Pharma in the 3rd quarter worth approximately $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the 1st quarter worth $35,000. Finally, First Horizon Corp bought a new position in BridgeBio Pharma in the 3rd quarter valued at $36,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results improve the commercial and regulatory outlook for BridgeBio’s achondroplasia program — a fundamental driver for longer‑term upside. PROPEL 3 Results
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and boosted its price target to $100 while maintaining a Buy — analyst upgrades can support buying interest and help re‑rate shares if fundamentals continue to improve. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst coverage remains constructive (multiple Buy/Overweight ratings and higher targets), which can amplify rallies following positive clinical/financial news. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this is the next near‑term catalyst that could drive volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to new hires (~76,701 shares aggregate) — modest ongoing share‑based comp that could be a small dilution factor to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer reported a small new 13F position (~7,845 shares) — modest institutional interest but not yet material to the register. Oppenheimer 13F
• Neutral Sentiment: Short‑interest reporting for Feb. 19 shows anomalous/zero values in the feed (likely a data/reporting glitch) — no clear evidence of a meaningful short squeeze or build from this item alone.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal W. Scott sold 10,000 shares and senior officers (CFO and CAO) also disclosed sales (CFO ~13,600 shares; CAO 510 shares) — concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Ongoing pattern of executive liquidity events highlighted in reporting — repeated insider selling can keep downward pressure on the stock until insiders demonstrate renewed accumulation. Insider/Sentiment Summary

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.